PCN189 COST-EFFECTIVENESS ANALYSIS OF PALBOCICLIB PLUS FULVESTRANT VERSUS EVEROLIMUS PLUS EXEMESTAN IN THE TREATMENT OF ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE, ADVANCED BREAST CANCER IN IRAN
Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.385
https://www.valueinhealthjournal.com/article/S1098-3015(19)32763-9/fulltext
Title :
PCN189 COST-EFFECTIVENESS ANALYSIS OF PALBOCICLIB PLUS FULVESTRANT VERSUS EVEROLIMUS PLUS EXEMESTAN IN THE TREATMENT OF ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE, ADVANCED BREAST CANCER IN IRAN
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)32763-9&doi=10.1016/j.jval.2019.09.385
First page :
Section Title :
Open access? :
No
Section Order :
10317